Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition containing prasugrel and rosuvastatin, and purpose thereof

A technology of rosuvastatin and rosuvastatin calcium, which is applied in the field of pharmaceutical compositions containing prasugrel and rosuvastatin, can solve the problem of single symptoms, unsustainable effect of prasugrel-like drugs, and treatment Insufficient effect and other problems, to achieve the effect of reducing toxic side effects, reducing prasugrel resistance, reducing the incidence of atherosclerosis and cardiovascular and cerebrovascular thrombosis events

Active Publication Date: 2015-05-13
LUNAN PHARMA GROUP CORPORATION
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] In order to overcome the shortcomings of the prior art that the existing drugs for cardiovascular and cerebrovascular diseases have single symptoms and poor therapeutic effect, prasugrel-like drugs have resistance phenomenon in the human body, and the effect of single drug administration cannot last, the present invention provides a new Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing prasugrel and rosuvastatin, and purpose thereof
  • Pharmaceutical composition containing prasugrel and rosuvastatin, and purpose thereof
  • Pharmaceutical composition containing prasugrel and rosuvastatin, and purpose thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1 compound prasugrel suvastatin tablet

[0028]

[0029] Preparation process: Weigh the prescribed amount of rosuvastatin, prasugrel, starch, dextrin and low-substituted hydroxypropyl cellulose and mix evenly. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After the drying is completed, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

Embodiment 2

[0030] Embodiment 2 compound prasugrel suvastatin tablet

[0031]

[0032]Preparation process: Weigh the prescribed amount of rosuvastatin, prasugrel, microcrystalline cellulose and hydroxypropyl cellulose and mix evenly. Take another appropriate amount of 8% starch slurry solution, add it to the mixed powder, mix evenly to make a soft material, pass through a 16-mesh sieve to granulate, and dry below 60°C. After the drying is completed, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

Embodiment 3

[0033] Embodiment 3 compound prasugrel suvastatin tablet

[0034]

[0035] Preparation process: Weigh the prescribed amount of rosuvastatin, prasugrel, starch, dextrin and low-substituted hydroxypropyl cellulose and mix evenly. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After the drying is completed, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicines, and discloses a pharmaceutical composition used for treating cardiovascular and cerebrovascular diseases. According to the pharmaceutical composition provided by the invention, prasugrel or a pharmaceutically acceptable salt thereof, and rosuvastatin or a pharmaceutically acceptable salt thereof are adopted as pharmaceutically active ingredients. Rosuvastatin or the pharmaceutically acceptable salt thereof is calculated according to rosuvastatin, and prasugrel or the pharmaceutically acceptable salt thereof is calculated according to prasugrel. In the pharmaceutical composition, the weight ratio of rosuvastatin to prasugrel is 1:0.01-100, and preferably 1:0.2-20. When the pharmaceutical composition is applied in treating cardiovascular and cerebrovascular diseases, the effect is comprehensive, the toxic and side effects are low, and patient compliance can be improved. Therefore, the pharmaceutical composition has good medical application prospect.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition containing prasugrel and rosuvastatin and its application. Background technique [0002] Cardiovascular and cerebrovascular diseases include coronary heart disease, angina pectoris, myocardial infarction, congestive pulmonary heart disease, ischemic encephalopathy, cerebral thrombosis, hypertension, hyperlipidemia, etc. The main cause of these diseases is that arteriosclerosis causes narrowing of the lumen and blockage of the pipeline, which leads to insufficient blood supply to the heart and brain, causing symptoms such as dizziness, dizziness, headache, and chest tightness. In severe cases, it can lead to stroke and myocardial infarction. Cardiocerebral ischemia affects energy metabolism, secondary to various changes such as lactic acid accumulation, calcium overload, and free radical damage. Multi-target reversal or improvement of these changes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/505A61K31/4365A61P9/10A61P7/02
Inventor 赵志全李斌王洪臣
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com